Study to Investigate the Effect of the A1 Agonist Capadenoson on Ventricular HR in Patients With Persistent or Permanent Atrial Fibrillation.
NCT00568945
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
28
Enrollment
INDUSTRY
Sponsor class
Conditions
Atrial Fibrillation
Interventions
DRUG:
Capadenoson (BAY68-4986)
Sponsor
Bayer